XML 15 R5.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Operating activities:    
Net Income (Loss) $ 254 $ (12,395)
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Stock-based compensation expense 5,308 7,945
Depreciation and amortization 1,162 1,330
Amortization of debt discount 311 180
Amortization of debt issuance costs 106 104
Accretion of discount on short-term investments (520) (1,211)
Retirement and impairment of property and equipment   3,441
Loss on disposal of property and equipment 95  
Change in operating assets and liabilities:    
Accounts receivable (1,050) (13,571)
Inventory (19,805) (754)
Prepaid expenses and other assets 698 67
Accounts payable 328 6,986
Accrued clinical and manufacturing liabilities (8,083) (4,605)
Accrued payroll and employee related liabilities (3,083) (2,139)
Other accrued expenses 4,541 502
Net cash used in operating activities (19,738) (14,120)
Investing activities:    
Purchases of short-term investments (32,087) (65,100)
Maturities and sales of short-term investments 41,958 69,063
Purchases of property and equipment (317) (637)
Proceeds from sale of property and equipment 53  
Net cash provided by investing activities 9,607 3,326
Financing activities:    
Receipts for stock issued under the equity incentive plan 258 328
Proceeds from purchases under the employee stock purchase plan 587 175
Net cash provided by financing activities 845 503
Net decrease in cash and cash equivalents (9,286) (10,291)
Cash and cash equivalents at beginning of period 25,802 28,677
Cash and cash equivalents at end of period 16,516 18,386
Supplemental disclosure of cash flow information:    
Interest paid $ 2,412 $ 2,426